Powered by

Are Regeneron's Libtayo hopes ‘hubris' or can it really dominate I-O combos?

Nov 06, 2019 - FiercePharma
Financial Results

Regeneron's sixth-to-market PD-1 inhibitor Libtayo has been slow to catch on, but the company hopes to make headway in new markets and with combination immuno-oncology regimens. But analysts aren't optimistic about the drug's growth prospects, and newly released data isn't calming their fears.

It's never easy being the sixth contender in any drug class, but for Regeneron, it's been particularly challenging to market the PD-1 inhibitor Libtayo—even though it was the first in the field app...